Abstract
Background Hong Kong, has operated under a zero-Covid policy in the past few years. As a result, population immunity from natural infections has been low. The ‘fifth wave’ in Hong Kong, caused by the Omicron variant, grew substantially in February 2022 during the transition from winter into spring. The daily number of reported cases began to decline quickly in a few days after social distancing regulations were tightened and rapid antigen test (RAT) kits were largely distributed. How the non-pharmaceutical interventions (NPIs) and seasonal factors (temperature and relative humidity) could affect the spread of Omicron remains unknown.
Methods We developed a model with stratified immunity, to incorporate antibody responses, together with changes in mobility and seasonal factors. After taking into account the detection rates of PCR test and RAT, we fitted the model to the daily number of reported cases between 1 February and 31 March, and quantified the associated effects of individual NPIs and seasonal factors on infection dynamics.
Findings Although NPIs and vaccine boosters were critical in reducing the number of infections, temperature was associated with a larger change in transmissibility. Cold days appeared to drive Re from about 2–3 sharply to 10.6 (95%CI: 9.9–11.4). But this number reduced quickly below one a week later when the temperature got warmer. The model projected that if weather in March maintained as February’s average level, the estimated cumulative incidence could increase double to about 80% of total population.
Interpretation Temperature should be taken into account when making public health decisions (e.g. a more relaxed (or tightened) social distancing during a warmer (or colder) season).
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
City University of Hong Kong (9610416)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
